Biocorrx Stock Performance
| BICX Stock | USD 0.30 0.06 16.67% |
On a scale of 0 to 100, BioCorRx holds a performance score of 4. The firm shows a Beta (market volatility) of 0.79, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, BioCorRx's returns are expected to increase less than the market. However, during the bear market, the loss of holding BioCorRx is expected to be smaller as well. Please check BioCorRx's treynor ratio, as well as the relationship between the semi variance and rate of daily change , to make a quick decision on whether BioCorRx's price patterns will revert.
Risk-Adjusted Performance
4 of 100
Weak | Strong |
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in BioCorRx are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of fairly fragile fundamental indicators, BioCorRx showed solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 592.1 K | |
| Total Cashflows From Investing Activities | -50 K |
BioCorRx |
BioCorRx Relative Risk vs. Return Landscape
If you would invest 30.00 in BioCorRx on August 30, 2024 and sell it today you would earn a total of 0.00 from holding BioCorRx or generate 0.0% return on investment over 90 days. BioCorRx is currently generating 0.7497% in daily expected returns and assumes 12.8937% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than BioCorRx, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
BioCorRx Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for BioCorRx's investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as BioCorRx, and traders can use it to determine the average amount a BioCorRx's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0581
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | BICX | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 12.89 actual daily | 96 96% of assets are less volatile |
Expected Return
| 0.75 actual daily | 14 86% of assets have higher returns |
Risk-Adjusted Return
| 0.06 actual daily | 4 96% of assets perform better |
Based on monthly moving average BioCorRx is performing at about 4% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of BioCorRx by adding it to a well-diversified portfolio.
BioCorRx Fundamentals Growth
BioCorRx OTC Stock prices reflect investors' perceptions of the future prospects and financial health of BioCorRx, and BioCorRx fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on BioCorRx OTC Stock performance.
| Return On Asset | -2.52 | |||
| Operating Margin | (33.51) % | |||
| Current Valuation | 13.9 M | |||
| Shares Outstanding | 7.63 M | |||
| Price To Earning | 3.61 X | |||
| Price To Book | 209.37 X | |||
| Price To Sales | 42.21 X | |||
| Revenue | 48.27 K | |||
| EBITDA | (4.48 M) | |||
| Cash And Equivalents | 81.76 K | |||
| Cash Per Share | 0.01 X | |||
| Total Debt | 174.16 K | |||
| Debt To Equity | 5.72 % | |||
| Book Value Per Share | (0.93) X | |||
| Cash Flow From Operations | (3.54 M) | |||
| Earnings Per Share | (0.69) X | |||
| Total Asset | 819.98 K | |||
| Retained Earnings | (62.83 M) | |||
| Current Asset | 312.06 K | |||
| Current Liabilities | 3.76 M | |||
About BioCorRx Performance
Evaluating BioCorRx's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if BioCorRx has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if BioCorRx has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
BioCorRx Inc., through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders in the United States. The company was formerly known as Fresh Start Private Management, Inc. and changed its name to BioCorRx Inc. in January 2014. Biocorrx operates under Medical Care Facilities classification in the United States and is traded on OTC Exchange.Things to note about BioCorRx performance evaluation
Checking the ongoing alerts about BioCorRx for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for BioCorRx help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| BioCorRx is way too risky over 90 days horizon | |
| BioCorRx has some characteristics of a very speculative penny stock | |
| BioCorRx appears to be risky and price may revert if volatility continues | |
| BioCorRx has a very high chance of going through financial distress in the upcoming years | |
| BioCorRx currently holds 174.16 K in liabilities with Debt to Equity (D/E) ratio of 5.72, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. BioCorRx has a current ratio of 0.08, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist BioCorRx until it has trouble settling it off, either with new capital or with free cash flow. So, BioCorRx's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like BioCorRx sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for BioCorRx to invest in growth at high rates of return. When we think about BioCorRx's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the previous year's revenue of 48.27 K. Net Loss for the year was (5.21 M) with profit before overhead, payroll, taxes, and interest of 42.39 K. | |
| BioCorRx currently holds about 81.76 K in cash with (3.54 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. | |
| Roughly 59.0% of BioCorRx shares are held by company insiders |
- Analyzing BioCorRx's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether BioCorRx's stock is overvalued or undervalued compared to its peers.
- Examining BioCorRx's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating BioCorRx's management team can have a significant impact on its success or failure. Reviewing the track record and experience of BioCorRx's management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of BioCorRx's otc stock. These opinions can provide insight into BioCorRx's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for BioCorRx OTC Stock Analysis
When running BioCorRx's price analysis, check to measure BioCorRx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioCorRx is operating at the current time. Most of BioCorRx's value examination focuses on studying past and present price action to predict the probability of BioCorRx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioCorRx's price. Additionally, you may evaluate how the addition of BioCorRx to your portfolios can decrease your overall portfolio volatility.